Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00421122
Status:
COMPLETED
Last Update Posted:
2009-03-27
First Post:
2007-01-09
Brief Title:
Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 6-Month Phase IIIA Multi-CenterRandomisedDouble-Blind Double-Dummy Parallel-Group Study of the Efficacy and Safety of Symbicort Turbuhaler Bricasol pMDI Compared With Pulmicort TurbuhalerBricasol pMDI in Chinese Patients With COPD
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims at evaluating efficacy and safety of Symbicort Turbuhaler in Chinese COPD patients as defined by GOLD treatment guidelines in order to obtain an approval for indication of COPD from Chinese State Food and Drug Administration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None